The immune system and response to HER2-targeted treatment in breast cancer
Giampaolo Bianchini, Luca Gianni · The Lancet Oncology · 2014
Cited by 286 works. doi:10.1016/s1470-2045(13)70477-7
Authors
References
- Hallmarks of Cancer: The Next Generation
- Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
- Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER2
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
- Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer
- Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma
- Nivolumab plus Ipilimumab in Advanced Melanoma
- erb B-2 Is a Potent Oncogene When Overexpressed in NIH/3T3 Cells
- Cancer Immunoediting: Integrating Immunity’s Roles in Cancer Suppression and Promotion
- Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets